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ABSTRACT
Introduction: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality world-
wide with a prevalence rate of approximately 6%. Although most cases of PPH have no identifi-
able risk factors, the incidence of PPH has been associated to the thromboprophylaxis in
pregnancy with low molecular weight heparin (LMWH). Thus, the aim of the study is to evaluate
the risk of PPH in cases of pregnant women exposed to LMWH.
Materials and methods: Electronic research was performed in OVID, Scopus, ClinicalTrials.gov,
MEDLINE, the PROSPERO International Prospective Register of Systematic Reviews, EMBASE, and
the Cochrane Central Register of Controlled Trials through April 2016. We included randomized
controlled trials, cohort and case-control studies of women who underwent thromboprophylaxis
with LMWH during pregnancy compared to a control group (either placebo or no treatment).
The primary outcome was the incidence of PPH. The summary measures were reported as rela-
tive risk (RR) or as mean differences (MD) with 95% confidence interval (CI).
Results: Eight studies including 22,162 women were analyzed. Of the 22,162 women, 1320 (6%)
were administered LMWH, 20,842 (94%) women formed the nonexposed group (control group).
Women treated with LMWH had a higher risk of PPH (RR 1.45, 95%CI 1.02–2.05) compared to
controls; there was no difference in mean of blood loss at delivery (MD 32.90, 95%CI
68.72–2.93) and in risk of blood transfusion at delivery (RR 1.24, 95%CI 0.62–2.51), respectively.
Conclusions: Women who receive LMWH during pregnancy have a significantly higher risk of
developing PPH. Women who receive LMWH during pregnancy have neither significantly higher
mean blood loss at delivery nor higher risk of blood transfusion.
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Introduction
Postpartum hemorrhage (PPH) is the leading cause of
maternal mortality worldwide with a prevalence rate
of approximately 6% [1]. PPH is responsible for about
25% of maternal deaths worldwide, and 12% of survi-
vors will have severe anemia. Clinically, it is associated
with weakness, sweating, and tachycardia, and with
hemodynamic collapse occurring at losses of between
35 and 45% of blood volume [2]. According to the
World Health Organization (WHO), PPH is defined as
“blood loss from the birth canal in excess of 500mL
during the first 24 h after delivery”, although currently
there is a debate about what definition to use [3].
The most common risk factors for PPH are the pres-
ence of suspected or proven placental abruption, pla-
centa previa, multiple pregnancy, macrosomia and
prolonged labor, retained placenta or cotyledons, uter-
ine hypotonia, major perineal lacerations and vaginal
hematoma, coagulation disorders, and prolonged oxy-
tocin use [4]. On the other hand, most cases of PPH
have no identifiable risk factors. The incidence of PPH
has been also associated to the use of thrombopro-
phylaxis in pregnancy with low molecular weight hep-
arin (LMWH). LMWHs are anticoagulants used mostly
in pregnant women with risk factors for deep venous
thrombosis (DVT) or pulmonary embolism (PE) in order
to avoid the incidence of venous thromboembolism
(VTE) and the related adverse outcomes in pregnancies
[5]. The safety of LMWH for the fetus has been
assessed since it does not pass the placental barrier
[6]; nevertheless, the role of anticoagulant has been
postulated to determine a higher risk of PPH.
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In 2005, a systematic review of safety and efficacy
assessed that LMWHs are not associated with an
increased risk of severe peripartum bleeding [7].
However, so far the risk of PPH in women using
LMWH during pregnancy is still the subject of debate
and up-to-date literature include different studies with
opposing results. Thus, the aim of this meta-analysis is
to evaluate the risk of PPH in cases of pregnant
women exposed to LMWHs.
Materials and methods
Search strategy
The research protocol was designed a priori [8], and
registered on Prospero (registration number:
CRD42016049373). We performed electronic research in
OVID, Scopus, ClinicalTrials.gov, MEDLINE, the
PROSPERO International Prospective Register of
Systematic Reviews, EMBASE, and the Cochrane Central
Register of Controlled Trials with the use of a combin-
ation of text words related to “heparin”, “low molecular
weight heparin”, “lmwh”, “postpartum hemorrhage”,
“pph”, “anticoagulation”, “thromboprophylaxis”, and
“pregnancy” through April 2016. No restrictions for lan-
guage or geographic location were applied.
Study selection
We included all randomized controlled trials (RCTs),
cohort, and case-control studies of women who under-
went thromboprophylaxis with LMWH during the third
trimester of pregnancy compared to a control group
(either placebo or no treatment). All the studies were
eligible if they reported the incidence of PPH after any
exposure to LMWHs and had a comparison group of
unexposed pregnant women. Studies without a control
group were excluded. Only studies reporting the inci-
dence of PPH as outcome were included. Studies on
LMWH during delivery or after delivery were not
included in the meta-analysis.
Risk of bias
The risk of bias of the included studies was assessed
via the Methodological Index for Non-Randomized
Studies (MINORS) [9]. Seven domains related to risk
bias were assessed in each study: (1) aim (i.e. clearly
stated aim), (2) rate (i.e. inclusion of consecutive
patients and response rate), (3) data (i.e. prospective
collection of data), (4) bias (i.e. unbiased assessment
of study end points), (5) time (i.e. follow-up time
appropriate), (6) loss (i.e. loss to follow-up), and (7)
size (i.e. calculation of the study size). Review authors’
judgments were categorized as “low risk”, “high risk”,
or “unclear risk of bias”.
Data extraction
Two authors (AS, GS) independently assessed inclusion
criteria, risk of bias and data extraction. Disagreements
were resolved by consensus through discussion. Data
from each eligible study were extracted without modi-
fication of original data onto custom-made data collec-
tion forms. Differences were reviewed, and further
resolved by common review of the entire process.
The primary outcome was the incidence of PPH, as
defined by the original studies. Secondary outcome
were mean blood loss and incidence of blood transfu-
sion at delivery. We planned sensitivity analysis accord-
ing to the study design of the included studies. All
analyses were performed using an intention-to-treat
approach, evaluating women according to the group
of allocation in the original studies.
All authors of the original studies were contacted in
case of missing data.
The following post hoc subgroup analyses were
assessed for the primary outcome:
 According to mode of delivery
 According to type of LMWH
 According to dose of LMWH
 According to indication of LMWH
Data analysis
The data analysis was completed independently by
two authors (AS, GS) using Review Manager 5.3
(Copenhagen: The Nordic Cochrane Centre, Cochrane
Collaboration, 2014). The completed analyses were
then compared, and any difference was resolved with
review of the entire data and independent analysis.
Between-study heterogeneity was explored using the
I2 statistic, which represents the percentage of
between-study variation that is due to heterogeneity
rather than chance [8]. A value of 0% indicates no
observed heterogeneity, whereas I2 values of 50%
indicate a substantial level of heterogeneity. A fixed
effects model was used if substantial statistical hetero-
geneity was not present. On the contrary, if there was
evidence of significant heterogeneity between studies
included, a random effect model was used [7]. We
planned to assess potential publication biases by using
Begg’s and Egger’s tests statistically, and by using the
funnel plot graphically.
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The summary measures were reported as relative
risk (RR) or as mean differences (MD) with 95% confi-
dence interval (CI). p Value<.05 was considered as
statistically significant. The meta-analysis was reported
following the Preferred Reporting Item for Systematic
Reviews and Meta-analyses (PRISMA) statement [10].
Results
Study selection and study characteristics
Nine articles were assessed for eligibility [11–19]. The
RCT of Howell et al. was excluded since they used
unfractionated heparin and not LMWH [19]. Eight stud-
ies including 22,162 women were therefore analyzed
(Figure 1) [11–18].
Risk of publication bias was assessed by visual
inspection of the funnel plot, and the symmetric plot
suggested no publication bias (Figure 2). Publication
bias, assessed statistically using Begg’s and Egger’s
tests, showed no significant bias (p¼ .47 and p¼ .51,
respectively). The statistical heterogeneity between the
studies was low.
Most of the included studies had low risk of bias in
“aim”, “rate”, “time”, and “follow-up”. Two of them
were prospective. Four studies were large retrospective
cohort studies. The most used types of LMWH were
dalteparin, enoxaparin, tinzaparin, and nadroparin
(Figure 3).
Table 1 shows the characteristics of the included
studies. Of the 22,162 women, 1320 (6%) were admin-
istered LMWH during pregnancy, and 20,842 (94%)
women formed the nonexposed group (control group).
One study came from the UK [18], two from the
Netherlands [14,16] one from the US [12], one from
France [17], and the rest from the northern Europe
[11,13,15]. All the included studies had PPH as primary
outcome.
In the eligible studies, PPH was defined as blood
loss >600mL [11], blood loss >500mL for vaginal
delivery and >1000mL for cesarean delivery (CD)
[12,16], blood loss 1000mL [13,15,17], and blood loss
500mL [14,18]. In the eligible studies, blood loss was
assessed during delivery [11–13,15] or within 24 hours
of delivery [14,16–18].
The indications for therapy with LMWH were mostly
history of VTE or adverse obstetric outcome, the pres-
ence of thrombophilia or a mechanical valve
replacement.
Regarding the LMWH therapy, in Lindqvist et al.
[11] Boilot et al. [17], and Galambosi et al. [15] women
were treated with dalteparin 5000 IU/day or enoxa-
parin 40mg/day; Andersen et al. used tinzaparin
4500 IU/day or dalteparin 5000 IU/day [13]; Knol et al.
therapeutic dose of nadroparin 95 UI/kg twice daily
[16]; Kominiarek et al. Enoxaparin 40mg twice/day;
dalteparin 5000 UI twice/day in case of prosthetic
mitral valve [12]; while Roshani et al. used various type
of LMWH including enoxaparin, dalteparin, nadroparin,
danaparoid, and tinzaparin [14].
In all studies, women in the control group received
no anticoagulation or antiplatelet therapy.
Gestational age at onset of therapy was various, but
all studies excluded those women who did not receive
LMWH in the third trimester. In most of the included
studies therapy was discontinued at onset of labor or
Figure 1. Flow diagram of studies identified in the systematic
review. (Prisma template [Preferred Reporting Item for
Systematic Reviews and Meta-analyses]).
Figure 2. Funnel plot for assessing publication bias. OR: odds
ratio; SE: standard error.
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at time of induction or at least 12 or 24 hours before
scheduled CD (Table 2).
Synthesis of results
We found that women treated with LMWH during
pregnancy had a significantly higher risk of PPH (RR
1.45, 95%CI; 1.02–2.05; Figure 4) compared to controls;
while no differences were found in the mean of blood
loss at delivery (MD 32.90, 95%CI; 68.72to 2.93;
Figure 5) and in risk of blood transfusion at delivery
(RR 1.24, 95%CI; 0.62–2.51; Figure 6).
Sensitivity analyses according to the study design
of the included studies, concurred with the overall
analysis for prospective (RR 3.42, 95%CI; 2.09–5.61) but
not for retrospective studies (RR 1.16, 95%CI;
0.92–1.47).
Subgroup analyses in cesarean delivery only (RR
1.52, 95% CI; 1.22–1.88) and vaginal delivery (RR 1.20,
95% CI; 1.17–1.64) only concurred with the overall
analysis.
Discussion
Main findings
This meta-analysis shows that women who received
LMWH during pregnancy had a significantly higher risk
of developing PPH. Women who received LMWH dur-
ing pregnancy had neither significantly higher mean
blood loss at delivery nor higher risk of blood
transfusion.
Comparison with existing literature
To date, most meta-analyses have investigated the
role of LMWH in reducing the risk of miscarriage in
women with recurrent pregnancy loss [20] or in reduc-
ing the prevalence of preeclampsia and small for ges-
tational age babies in women with a history of
preeclampsia [21]. To our knowledge, this is the first
systematic review evaluating the possible association
between the administration of LMWH during preg-
nancy and the risk of PPH.
Strengths and limitations
The most important strength of our work rest on the
large number of women included. When considering
the incidence of PPH for each single study, only two
studies included reach a significant result but with a
moderate number of women included [16,18]. Most of
the included studies have a low risk of bias. All the
eight studies had PPH as primary outcome.
Although meta-analytical techniques pool all avail-
able data, limitations include those of the original
articles. Only two studies were prospective and six
were retrospective cohort studies. Furthermore, five
studies did not report the exact dosage of LMWH
administered to pregnant women and two studies did
not report the definition of PPH. None of the included
studies adjusted data for confounders and this is the
major shortcoming of this review. As LMWH use occurs
mainly in the context of maternal risk of thrombo-
embolic events, we were not able to study the effects
Figure 3. Assessment of risk of bias. Aim, clearly stated aim; Rate, inclusion of consecutive patients and response rate; Data, pro-
spective collection of data; Bias, unbiased assessment of study end points; Time, follow-up time appropriate; Loss, loss to follow-
up; Size, calculation of the study size. (A) Summary of risk of bias for each study. Plus sign, low risk of bias; minus sign, high risk
of bias; question mark, unclear risk of bias. (B) Risk of bias graph about each risk of bias item presented as percentages across all
included studies.
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of LMWH exposure independent of exposure to
thromboembolic risk. This bias cannot be reliably elim-
inated with a multivariable analysis. Based on the char-
acteristics of the included studies and the summary
statistics for heterogeneity there was a large amount
of both statistical and clinical heterogeneity. The stud-
ies vary markedly by overall study design, analysis,
drug exposure, drug type, and definition of the main
outcome. The statistical heterogeneity within the stud-
ies for the primary outcome was high (I2¼ 71%). For
this reason, random effects models were used in the
analysis performed. Another major issue is the small
OR (1.45 for the primary outcome). The primary out-
come may be statistically, but not clinical significant.
Maybe the existing studies pooled together for this
review did not adequately address the question, espe-
cially as no RCTs were included. No data were avail-
able on the assessment methods of mean blood loss
at delivery and on the indications and hemoglobin
thresholds for red blood cell transfusion. Subgroup
analyses were post hoc and not planned a priori.
Interpretation
Metabolic changes during pregnancy enhance the risk
of venous thromboembolic events (VTE) [21,22]. For
this reason women with history of VTE, thrombophilia
or other conditions at risk, such as a mechanical heart
valve, undergo an anticoagulant prophylaxis during
pregnancy to reduce the risk of VTE. LMWH is consid-
ered as the gold standard drug for prophylaxis and
therapy of VTE during pregnancy because it does not
pass through the placenta and thus there is no terato-
genic risk for the fetus [7]. Furthermore, since pree-
clampsia has been shown to be linked to an increased
risk of VTE and at the same time the thrombophilic
state in preeclampsia has been linked to a worsened
perinatal outcome of the pregnancy, also women with
history of preeclampsia or fetal growth restriction usu-
ally undergo a thromboprophylaxis during pregnancy,
even if at the moment there is no unanimous consen-
sus on this strategy. However, a recent meta-analysis
showed that the addition of LMWH to low-dose aspirin
could reduce the prevalence of preeclampsia and
small for gestational age babies in women with a his-
tory of preeclampsia [20]. Simonazzi et al. found that
prophylactic tranexamic acid given before cesarean
skin incision in women undergoing cesarean delivery,
under spinal or epidural anesthesia, significantly
decreases blood loss, including PPH and severe PPH,
in addition to the standard prophylactic oxytocin given
after delivery of the neonate, but women receiving
LMWH therapy were not included in this study [4,23].Ta
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The biological plausibility of our findings is not
completely clear. With respect to PPH, LMWH-related
risk of bleeding is usually considered low when admin-
istration is suspended 12 hours before delivery [24,25].
It is not clear whether a chronic exposure to LMWH
during pregnancy may lead to modifications on the
decidual architecture and the uterine wall at term,
thus increasing the hemorrhagic risk even if LMWH is
suspended according to the present recommenda-
tions. On the other hand, untreated women with
increased thromboembolic risk may be at higher risk
for VTE.
Furthermore, the significant increased incidence of
PPH but not of mean blood loss at delivery or transfu-
sion could be explained considering the small number
of women included in the secondary analysis (784 for
mean blood loss at delivery, 883 for blood transfusion)
compared to the women included in the primary ana-
lysis (22,162). Since no data were available on the
assessment methods of mean blood loss at delivery
and on the indications and hemoglobin thresholds for
red blood cell transfusion, it seems difficult to evaluate
the clinical significance of these findings.
Conclusions
In summary, based on this findings treatment with
LMWH during pregnancy may be associated with an
increased risk of PPH. Hence, in situations where it
may be necessary to use LMWHs in pregnancy (prior
history of VTE, thrombophilia, mechanical heart valve,
previous obstetric complications), the decision to use
Figure 5. Forest plot for the mean of blood loss. M-H: Mantel–Haenszel test; CI: confidence interval.
Figure 6. Forest plot for the risk of blood transfusion at delivery. M-H: Mantel–Haenszel test; CI: confidence interval.
Figure 4. Forest plot for the risk of postpartum hemorrhage. M-H: Mantel–Haenszel test; CI: confidence interval.
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LMWHs during pregnancy must be weighed against
this risk/benefit ratio, including the risk of PPH. This
must be carefully discussed with the woman, and
should ideally be done in collaboration with the expert
in hemostasis and thrombosis.
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